Arrowhead Pharmaceuticals Says Phase 3 Study of Plozasiran Met Primary Endpoint

05:15 AM EDT, 09/03/2024 (MT Newswires) -- Arrowhead Pharmaceuticals (ARWR) said Monday a phase 3 study of investigational plozasiran in patients with familial chylomicronemia syndrome met its primary endpoint and all multiplicity-controlled key secondary endpoints.

Familial chylomicronemia syndrome is a genetic disease often caused by monogenic mutations, leading to very high triglyceride levels and causing various serious symptoms.

Plozasiran reduced triglycerides by 80% from baseline and lowered the risk of developing acute pancreatitis by 83%, the company said.

Arrowhead plans to file a new drug application with the US Food and Drug Administration by the end of 2024 and also seek regulatory approval from other authorities thereafter.

Price: 23.60, Change: -0.23, Percent Change: -0.97